{
  "docId": "019de076-8e54-70f4-b1ec-6643014b872e",
  "docSlug": "869b7bb859e037e0c2aa4b6e5865c5ed",
  "documentTitle": "AbCellera | Investor Conference Presentation Deck | 14 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 14,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a structured table to present key drug development metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8e54-70f4-b1ec-6643014b872e/8",
  "deckHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e",
  "deckJsonHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e.json",
  "deckAnchorHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.05,
        "x": 0.93,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*Source: IQVIA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4166dde6-52d1-46ed-8278-2a442486e4f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.08,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1. Croft M, et al. (2009) Immunol Rev. 229(1):173-91. 2. clinicaltrials.gov... 3. clinicaltrials.gov... 4. clinicaltrials.gov...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e67fe1f-c391-4f46-9f54-f22b76eed8c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.48,
        "x": 0.47,
        "y": 0.1
      },
      "kind": "table",
      "text": "Molecule: ABCL575; Status: IND-enabling studies; Target: OX40L; MOA: Blocking and non-depleting; Indication: Atopic dermatitis; Market Opportunity: $17B by 2032",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3cffdab-d97f-428d-8086-233d16ae729c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.09,
        "y": 0.24
      },
      "kind": "title",
      "text": "ABCL575 is a potential best-in-class and second-in-class antibody therapy for the treatment of atopic dermatitis.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a2f6234-a6d6-4f4e-b04b-24f73237e222",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.09,
        "y": 0.04
      },
      "kind": "title",
      "text": "OUR PIPELINE - ABCL575",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a71c7f2e-fe56-476f-8c1b-7c90fa1bb0d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}